CTAD 2023 | Amyloid reduction as a surrogate endpoint in Alzheimer’s disease trials: insights from DIAN-TU

Guoqiao Wang, PhD, Washington University School of Medicine, St Louis, MO, addresses the utilization of amyloid reduction as a surrogate endpoint in Alzheimer’s disease (AD) clinical trials and its correlation with clinical cognitive benefits, with a focus on insights from the DIAN-TU trial (NCT05269394). This controversial topic stems from trials in which amyloid reduction in response to treatment did not translate to cognitive improvements, prompting criticism of the amyloid hypothesis. While the DIAN-TU trial initially showed no treatment effect, the application of latent class analysis revealed an association between amyloid reduction and cognitive benefits. This interview took place at the CTAD 2023 conference in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.